)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
Geron (GERN) investor relations material
Geron Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary6 Aug, 2025
Executive summary
Achieved $49M in RYTELO net product revenue in Q2 2025, up 24% from Q1, with demand rising 17% and over 1,000 ordering accounts, up by 400 year-to-date.
Expanded commercial and medical affairs teams by over 20%, with new hires trained and deployed to drive further growth.
Appointed Harout Semerjian as President and CEO, bringing over 30 years of hematology and oncology experience.
Preparations underway for RYTELO launch in select EU countries in 2026 via third-party partners, following recent approval.
Over 95% enrollment reached in the Phase 3 ImpactMF trial for relapsed/refractory myelofibrosis, with full enrollment expected by year-end 2025.
Financial highlights
Q2 2025 net product revenue was $49M, up from $780K–$882K in Q2 2024, reflecting the first full quarters post-FDA approval.
Net loss for Q2 2025 was $16.4M ($0.02/share), a significant improvement from $67.4M ($0.10/share) in Q2 2024.
Operating expenses for Q2 2025 were $61.5M, down from $70.2M in Q2 2024; R&D expenses decreased 29% and SG&A down 2%.
Cash, cash equivalents, and marketable securities totaled $432.6M as of June 30, 2025, down from $502.9M at year-end 2024.
Six-month net product revenue reached $88.4M; six-month net loss was $36.2M versus $122.8M in the prior year period.
Outlook and guidance
FY 2025 operating expenses expected to be $270M–$285M, reflecting investments in commercialization, supply, and EU launch preparations.
Expanded commercial and medical teams expected to impact performance by year-end 2025.
Existing cash and anticipated RYTELO revenues expected to fund operations for the foreseeable future, with access to additional debt funding if needed.
European launch targeted for select markets in 2026, pending favorable reimbursement.
Company expects to reach profitability without additional financing if current sales and expense targets are met.
What drives earlier RYTELO line of therapy use?
What is the EU commercialization timeline?
What could accelerate IMpactMF data readout?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Geron earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
)
Edge19 Sep 2025
American Express: An Empire of Plastic
How history, brand, and structure have steadily built American Express' moat, and why Warren Buffett still calls it a one-of-a-kind business.
Frequently asked questions
Geron Corporation focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. The company has a portfolio of drugs in clinical trials that address a number of blood cancers, including acute myeloid leukemia (AML) and Acute Lymphoblastic Leukemia (ALL). In AML, it develops GRN163L/GRN163L-AQ, which is an oral small molecule Bruton's tyrosine kinase inhibitor (BTKi) initially planned for regulatory filing in the U.S., Canada, and Europe in the third quarter 2014 to treat patients with previously treated AML with FLT3 -ITD or V617F mutation and in the fourth quarter 2014 to treat patients with relapsed or refractory pediatric AML with FLT3-ITD or V617F mutation; GRN703/GRN703-AQ, an oral inhibitor of both Btk and IgE Fcepsilon receptors (FCER1A), which is being developed to treat patients with eosinophil-related diseases, including allergic asthma and atopic dermatitis.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage